GA
SRNE

GoalVest Advisory’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

GoalVest Advisory’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-32,915
Closed -$11.8K – 421
2023
Q1 		$11.8K Sell
32,915
-18,725
-36% -$16.8K 0.01% 178
2022
Q4 		$45.8K Buy
51,640
+18,025
+54% +$23.9K 0.03% 113
2022
Q3 		$53K Buy
+33,615
New +$76.3K 0.04% 109

Other funds holding SRNE

SW
SlateStone Wealth Jupiter, Florida $1.31B AUM 26.51% 1-Year Est. Return
KA
KLCM Advisors Milwaukee, Wisconsin $1.27B AUM 31.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return
AA
AlphaMark Advisors Ft. Wright, Kentucky $231M AUM 19.98% 1-Year Est. Return
OAJ
Ogorek Anthony Joseph Williamsville, New York $403M AUM 22.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
TCOV
Trust Company of Vermont Brattleboro, Vermont $2.68B AUM
CFGS
Concourse Financial Group Securities Birmingham, Alabama $1.77B AUM 17.37% 1-Year Est. Return

GoalVest Advisory's SRNE Position: Q2 2023 in Review

GoalVest Advisory sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2023, closing a stake of 32,915 shares — an estimated $11.8K sold.

GoalVest Advisory first reported a position in SRNE in Q3 2022 and held it in 3 quarters. The position peaked at $53K in Q3 2022. 9 funds tracked by Wall St. Rank hold SRNE as of Q2 2023.

  • GoalVest Advisory reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2023 after selling out during the quarter.
  • GoalVest Advisory sold 32,915 Sorrento Therapeutics, Inc. shares in Q2 2023, an estimated $11.8K.
  • GoalVest Advisory first reported a position in Sorrento Therapeutics, Inc. in Q3 2022 and held it in 3 quarters.
  • GoalVest Advisory's Sorrento Therapeutics, Inc. position peaked at $53K in Q3 2022.
  • 9 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2023.

Based on GoalVest Advisory's 13F filing for Q2 2023, filed 10 Jul 2023.